Previous news articles featured the history and technology behind two powerful tools for visualizing proteins in tissues: immunohistochemistry and microscopy. These tools are applied to investigate and answer a wide range of questions, both in healthcare and research. This article focuses on two applications related to lung cancer: diagnostics in clinical pathology and discovery of genes associated with prognosis...Read more
In two recent publications the group of Fredrik Pontén in Uppsala has identified two very strong, independent biomarkers for the prognostic stratification of breast cancer and renal cell carcinoma.
Renal cell carcinoma is the most common type of cancer affecting the kidney and there is an unmet clinical need for better prognostic and diagnostic tools for it. Diagnosis and subtyping of renal cell carcinoma are achieved through the morphological analysis of tumor sections. The application of immunohistochemistry can reveal important additional clues during the diagnostic work-up...Read more
During the Precision Medicine World Conference in Silicon Valley on January 23-25, Mathias Uhlen, leader of the Human Protein Atlas will give a talk about the recently initiated SCAPIS – SciLifeLab Wellness Profiling project.
The Precision Medicine World Conference is a conference series that attracts recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration...Read more
In a recent study in Journal of Proteome Research by Human Protein Atlas-researchers a new reactive epitope of a prostate specific protein, particularly reactive in the late stages of prostate cancer is identified.
According to WHO, prostate cancer is the second most incident cancer in men and the fifth leading cause of death in men worldwide, and there is a demand for novel targets and approaches to diagnose and treat this cancer type. Five-year survival is reached by almost 100% of patients if the disease is still at a local and regional stage; however, the survival rate drops down to 30% in the case of aggressive form with distant metastasis and relapse after treatment...Read more
In a recent study, published in Blood, researchers have used affinity reagents from the Human Protein Atlas project to analyze plasma samples to identify candidate protein markers associated with risk of venous thromboembolism.
Venous thromboembolism is the third most common cardiovascular disease and a leading cause of death and disability worldwide. Complex interactions between genetic, environmental and acquired risk factors underlie disease development. The first step in the process of developing clinically applicable predictive tools is the identification of novel markers that associate with the disease...Read more